Welcome to our dedicated page for Bausch Health Companies SEC filings (Ticker: BHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bausch Health Companies Inc. filings document regulatory disclosures for a global diversified pharmaceutical company incorporated in British Columbia. The record includes Form 8-K reports for quarterly and annual operating results, Regulation FD updates, clinical-program disclosures, material agreements, debt exchanges and credit-agreement refinancing involving Bausch Health and its subsidiaries, including Bausch + Lomb.
Proxy materials describe annual meeting matters, director elections, auditor approval, executive compensation votes and governance procedures. Other current reports address compensatory arrangements, including performance share unit settlement terms, and capital-structure disclosures tied to senior secured notes, guarantees, collateral arrangements and refinancing transactions.
Bausch Health Companies Inc. (BHC) reported that Aimee J. Lenar, President, US Pharma, sold 36,827 Common Shares on August 19, 2026 at $7.03 per share in an open‑market transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2026, and Lenar now holds 334,853 Common Shares directly.
Bausch Health Companies Inc. (symbol BHC) has a notice indicating that officer Aimee J. Lenar may sell common stock under Rule 144. The filing lists Fidelity Brokerage Services LLC as the broker and identifies the common stock as trading on the NYSE with a referenced date of 08/19/2026.
The notice itemizes several amounts associated with "Restricted Stock Vesting" from the issuer, categorized as compensation, with dates of 07/15/2025, 02/26/2026, 07/15/2026, and 07/17/2026. The document is signed by Wade Moss as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Aimee Lenar.
Bausch Health Companies Inc. delivered stronger quarterly results but a much weaker first half in 2026. For the three months ended June 30, 2026, total revenues were $2,852 million, up from $2,530 million in 2025, and net income attributable to Bausch Health rose to $258 million from $148 million. Basic earnings per share for the quarter increased to $0.69 from $0.40.
For the six‑month period, however, the company reported a net loss attributable to Bausch Health of $1,165 million versus net income of $90 million a year earlier, driven largely by a $1,426 million goodwill impairment in the Salix reporting unit following failed Phase 3 clinical trials. This contributed to a shift from positive equity to a total shareholders’ deficit of $1,771 million and total (deficit) equity of $(802) million as of June 30, 2026, with total assets of $24,794 million and total liabilities of $25,596 million.
Operating cash flow remained solid, with net cash provided by operating activities of $900 million for the first half of 2026, up from $500 million in 2025, and cash and cash equivalents increased to $1,825 million. Long‑term debt and other borrowings had principal amounts totaling $20,239 million, generating first‑half interest expense of $798 million. The company continues to pursue the separation of its majority‑owned Bausch + Lomb business, while Xifaxan® intangible assets carried a value of $808 million with an estimated remaining useful life of 18 months amid ongoing generics litigation.
Bausch Health reported strong results for the quarter ended June 30, 2026. Total consolidated revenue was $2.85 billion, up 13% on a reported basis and 11% on an organic basis versus the prior-year quarter. Revenue excluding Bausch + Lomb grew 16% reported and 13% organic, led by the Salix segment, where sales rose 21%, and Solta Medical, up 38% reported.
GAAP net income attributable to Bausch Health was $258 million, up from $148 million, with GAAP diluted EPS of $0.68. Adjusted net income attributable to Bausch Health was $476 million, and adjusted diluted EPS was $1.26, up from $0.90. Adjusted EBITDA attributable to Bausch Health increased to $1.08 billion from $842 million. Cash provided by operating activities reached $671 million, compared with $289 million a year earlier.
As of June 30, 2026, cash and cash equivalents were $1.83 billion including restricted cash, against total long-term debt of $20.74 billion. Management raised 2026 guidance, targeting consolidated revenue of $10.79–$11.04 billion and adjusted EBITDA of $4.05–$4.18 billion, with higher outlooks for revenue, adjusted EBITDA and adjusted cash flows from operations for the business excluding Bausch + Lomb.
Bausch Health Companies Inc. reported that Aimee J. Lenar, President, US Pharma, had 5,260 Common Shares withheld on 2026-07-17 at $4.83 per share to satisfy tax withholding obligations upon vesting of Restricted Share Units. After this tax-withholding disposition, she directly holds 371,680 Common Shares.
Aimee J. Lenar, President, US Pharma of Bausch Health Companies Inc., reported a tax-withholding disposition of 23,395 common shares on July 15, 2026 at $4.89 per share. The issuer withheld these shares to satisfy tax obligations on vested Restricted Share Units, leaving her with 376,940 common shares held directly.
Bausch Health Companies Inc. senior vice president, controller and chief accounting officer Steven Hyosig Lee reported a tax-withholding disposition of 3,125 common shares on July 14, 2026, at $4.75 per share, withheld by the issuer to satisfy tax obligations on vesting of Restricted Share Units. Following this, he directly holds 70,114 common shares.
Bausch Health Companies Inc. director Amy B. Wechsler received an equity-based compensation grant rather than cash for her board service for the quarter ending June 30, 2026. She was awarded 1,394 Restricted Share Units, each representing a contingent right to receive one common share.
The grant is recorded at a reference price of $4.93 per share and is classified as a non-derivative acquisition. Following this award, Wechsler’s direct holdings increased to 314,979 common shares, reinforcing that this is a routine compensation-related transaction rather than an open-market purchase.
Paulson John reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director John Paulson reported an equity-based compensation grant and updated his holdings. He received 12,677 Restricted Share Units, issued in lieu of cash compensation for his service on the board for the quarter ending June 30, 2026, each RSU representing one common share at a reference value of $4.93 per share.
Following this grant, Paulson holds 430,242 common shares directly. The filing also reports 73,255,869 common shares held indirectly by investment funds managed by Paulson Capital Inc., where he may be deemed an indirect beneficial owner, while disclaiming beneficial ownership except to the extent of any pecuniary interest.
Bausch Health Companies Inc. director Sandra Leung received an equity compensation grant rather than cash for her board service. She acquired 6,845 common shares on June 30, 2026, valued at $4.93 per share, in the form of Restricted Share Units for the quarter ending June 30, 2026.
Each unit represents a contingent right to receive one common share, and following this grant she directly holds a reported total of 97,070 common shares. This is a routine, compensation-related award rather than an open-market purchase or sale.